Beyond the Payload
In this Point of View Anthony Blaszczyk, PhD, principal scientist at USP provides insights on how delivery technologies will shape the future of cell and gene therapy. The post Beyond the Payload appeared first on GEN - Genetic Engineering and Biotechnology News .
Over the past ten years, cell and gene therapies (CGTs) have demonstrated the potential to alter disease-causing biological processes, restore missing cellular functions, and provide long-lasting therapeutic benefits following just one administration. However, despite substantial advancements in design and development, delivering genetic cargo efficiently, safely, and consistently to the appropriate cells remains a significant challenge.
The ability to reliably and consistently introduce the correct genetic material to the right cells is one of the most crucial factors in determining clinical success. While payload design will continue to be a primary focus, the next phase of CGT innovation may hinge more on the delivery vehicle itself. In many instances, delivery performance can directly impact therapeutic efficacy, safety, and manufacturability.
As payload technologies progress, delivery may emerge as the key factor separating scientific possibilities from clinical realities.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
